Safety of hymenoptera venom immunotherapy: a systematic review

Bibliography

• Antonicelli L, Bilo MB, Bonifazi F. Epidemiology of Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2002;2:341-6
   PubMedGoogle Scholar
• Hunt KJ, Valentine MD, Sobotka AK, A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978;299:157-61
   PubMed Web of Science ®Google Scholar
• Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of hymenoptera venom hypersensitivity: a meta-analysis. Clin Ther 2000;22:351-8
   PubMed Web of Science ®Google Scholar
• Lerch E, Muller UR. Long-term protection after stopping venom immunotherapy: results of re-sting in 200 patients. J Allergy Clin Immunol 1998;101:606-12
   PubMed Web of Science ®Google Scholar
• Golden DB, Kagey-Sobotka A, Lichtenstein LM. Survey of patients after discontinuing venom immunotherapy. J Allergy Clin Immunol 2000;105:385-90
   PubMed Web of Science ®Google Scholar
• Bonifazi F, Jutel M, Bilo MB, Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005;60:1459-70
   PubMed Web of Science ®Google Scholar
• Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000;55:484-8
   PubMed Web of Science ®Google Scholar
• Brockow K, Kiehn M, Riethmuller C, Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: a prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol 1997;100:458-63
   PubMed Web of Science ®Google Scholar
• Muller U, Lanner A, Schmid P, A double blind study on immunotherapy with chemically modified honey bee venom: monomethoxy polyethylene glycol-coupled versus crude honey bee venom. Int Arch Allergy Appl Immunol 1985;77:201-3
   PubMedGoogle Scholar
• Muller U, Akdis CA, Fricker M, Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-54
   PubMed Web of Science ®Google Scholar
• Mosbech H, Malling HJ, Biering I, Immunotherapy with yellow jacket venom. A comparative study including three different extracts, one adsorbed to aluminium hydroxide and two unmodified. Allergy 1986;41:95-103
   PubMedGoogle Scholar
• Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side effects during induction treatment. Clin Exp Allergy 2000;30:1423-9
   PubMed Web of Science ®Google Scholar
• Lockey RF, Turkeltaub PC, Olive ES, The Hymenoptera venom study. III: Safety of venom immunotherapy. J Allergy Clin Immunol 1990;86:775-80
   PubMed Web of Science ®Google Scholar
• Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992;89:529-35
   PubMedGoogle Scholar
• Birnbaum J, Charpin D, Vervloet D. Rapid Hymenoptera venom immunotherapy: comparative safety of three protocols. Clin Exp Allergy 1993;23:226-30
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy 1994;73:423-8
   PubMedGoogle Scholar
• Youlten LJF, Atkinson BA, Lee TH. The incidence and nature of adverse reactions to injection immunotherapy in bee and wasp venom allergy. Clin Exp Allergy 1995;25:159-65
   PubMedGoogle Scholar
• Laurent J, Smiejan JM, Bloch-Morot E, Safety of Hymenoptera venom rush immunotherapy. Allergy 1997;52:94-6
   PubMedGoogle Scholar
• Quercia O, Rafanelli S, Puccinelli P, Stefanini GF. The safety of cluster immunotherapy with aluminium hydroxide-adsorbed honey bee venom extract. J Investig Allergol Clin Immunol 2001;11:27-33
   PubMedGoogle Scholar
• Sturm G, Kranke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol 2002;110:928-33
   PubMed Web of Science ®Google Scholar
• Birnbaum J, Ramadour M, Magnan A, Vervloet D. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors. Clin Exp Allergy 2003;33:58-64
   PubMed Web of Science ®Google Scholar
• Wenzel J, Meissner-Kraemer M, Bauer R, Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients. Allergy 2003;58:1176-9
   PubMedGoogle Scholar
• Rueff F, Wolf H, Schnitker J, Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations. Allergy 2004;59:589-95
   PubMedGoogle Scholar
• Schiavino D, Nucera E, Pollastrini E, Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol 2004;92:409-13
   PubMed Web of Science ®Google Scholar
• Steiss JO, Jodicke B, Lindemann H. A modified ultrarush insect venom immunotherapy protocol for children. Allergy Asthma Proc 2006;27:148-50
   PubMedGoogle Scholar
• Pasaoglu G, Sin BA, Misirligil Z. Rush hymenoptera venom immunotherapy is efficacious and safe. J Investig Allergol Clin Immunol 2006;16:232-8
   PubMedGoogle Scholar
• Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol 2006;16:79-85
   PubMed Web of Science ®Google Scholar
• Quercia O, Emiliani F, Pecora S, Efficacy, safety, and modulation of immunologic markers by immunotherapy with honeybee venom: comparison of standardized quality depot versus aqueous extract. Allergy Asthma Proc 2006;27:151-8
   PubMedGoogle Scholar
• Alessandrini AE, Berra D, Lodi Rizzini F, Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy. Ann Allergy Asthma Immunol 2006;97:92-7
   PubMedGoogle Scholar
• Gorska L, Chelmimska M, Kuziemski K, Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy. Int Arch Allergy Immunol 2008;147:241-5
   PubMed Web of Science ®Google Scholar
• Kalogeromitros D, Makris M, Koti I, A simple 3-day rush venom immunotherapy protocol: documentation of safety. Allergol Immunopathol (Madr) 2010;38:69-73
   PubMed Web of Science ®Google Scholar
• Spoerl D, Bircher AJ, Scherer K. Safety profile of hymenoptera venom immunotherapy (VIT) in monosensitized patients: lack of new sensitization to nontreated insect venom. J Investig Allergol Clin Immunol 2011;21:22-7
   PubMedGoogle Scholar
• Wyss M, Cheitlin T, Stadler BM, Immunotherapy with aluminum hydroxide adsorbed insect venom extracts (Alutard SQ): immunologic and clinical results of a prospective study over 3 years. Allergy 1993;48:81-6
   PubMedGoogle Scholar
• Mosbech H, Muller U. Side-effects of insect venom immunotherapy: results from an EAACI multicenter study. Allergy 2000;55:1005-10
   PubMed Web of Science ®Google Scholar
• Stumpf JL, Shehab N, Patel AC. Safety of angiotensin-converting enzyme inhibitors in patients with insect venom allergies. Ann Pharmacoter 2006;40:699-703
   PubMed Web of Science ®Google Scholar
• Rueff F, Przybilla B, Bilo MB, Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase. J Allergy Clin Immunol 2010;126:105-11
   PubMed Web of Science ®Google Scholar
• Bilo MB, Antonicelli L, Bonifazi F. Purified vs. nonpurified venom immunotherapy. Curr Opin Allergy Clin Immunol 2010;10:330-6
   PubMed Web of Science ®Google Scholar